An unbranded injection pen rests beside a mechanical scale as an older person pauses in a clinic doorway.
Technology 8 min read

Wegovy Weight Loss May Fade After Stopping, With Wide Variation

In two trials, people regained weight on average after stopping injectable semaglutide. The results show why the last injection may be a poor endpoint.

DISCLAIMER

This article is for informational purposes only and does not constitute medical advice. The statements in this article have not been evaluated by the FDA. The information presented is based on published research and should not be used as a substitute for professional medical guidance. Consult your physician before starting any supplement or health protocol.

At week 20 of the STEP 4 trial, researchers switched 268 people from injectable semaglutide to a placebo injection, and the group’s average weight began to climb. For anyone weighing whether a course of Wegovy can end once the scale reaches a target, that turn in the trial curve may be more informative than the weight lost before it. STEP 4 randomized trial

The trial that switched the injection

Everyone who entered STEP 4 started on semaglutide, the active ingredient in Wegovy. Of 902 people who began that initial phase, 803 reached the trial’s maintenance regimen and qualified for randomization. They had lost an average of 10.6% of their starting weight over 20 weeks. Researchers then assigned 535 to continue semaglutide and 268 to switch to placebo. Both groups continued receiving lifestyle counseling, and participants and investigators were masked to the new assignments. STEP 4 randomized trial

Over the next 48 weeks, average weight fell another 7.9% in the group that stayed on semaglutide and rose 6.9% in the group switched to placebo. The percentages use weight at the point of randomization as the reference. In round numbers, for two hypothetical people who each weighed 100 kilograms at week 20, those group averages would correspond to roughly 92 and 107 kilograms at week 68. The example illustrates the size of the separation between the two study groups. Individual weight changes could be much smaller or larger. STEP 4 randomized trial

The trial’s design makes the comparison especially relevant to someone who has already tolerated the drug for several months. Both groups had the same chance of being assigned to either treatment after the initial phase, so the split in their weight curves is difficult to attribute simply to one group having been more successful at the outset. The design also narrows the finding. People who could not reach the maintenance regimen or left the study early were outside the randomized comparison. The result applies most directly to people who made it through that initial phase under trial conditions. STEP 4 randomized trial

One year off the drug, measured from the original starting weight

The STEP 1 extension followed a different group of participants after a longer period of treatment. Among the 327 people included in the extension analysis, those originally assigned to semaglutide had lost an average of 17.3% of starting weight by week 68. During the following year off treatment, they regained 11.6 percentage points of starting weight. They ended the extension an average of 5.6% below their original weight, using the study’s rounded estimates. The placebo group’s average ended close to its original weight. STEP 1 extension

The often-cited figure of two-thirds describes the share of the initial average loss regained, roughly 11.6 divided by 17.3. On a 100-kilogram starting scale, the trajectory would be approximately 100 to 83 to 94 kilograms. The distinction matters at both ends. A person can regain a substantial amount after stopping and still be below their starting weight at the next annual visit. The follow-up ended at that point, so the study leaves open whether weight would stabilize, rise further or fall again. STEP 1 extension

The study team also ended its structured lifestyle intervention at week 68. That makes the extension useful for understanding what may happen when both parts of a program end together, a situation that can arise when a treatment program closes or coverage changes. STEP 4 addresses a narrower question because counseling continued after the switch to placebo. Read together, the studies suggest that average regain can occur even when counseling continues. The two figures cannot quantify the added effect of losing counseling because the trials used different populations, treatment periods and reference weights. STEP 1 extension · STEP 4 randomized trial

The average leaves room for different outcomes

STEP 1 researchers observed that people who lost more during treatment tended to regain more after withdrawal. Those with larger initial losses also tended to retain a larger net loss at the end of follow-up. The two observations can hold for the same person. Someone who goes from 100 kilograms to 80 and then to 90 regains more kilograms than someone who goes from 100 to 92 and then to 97, while ending farther below the original weight. The examples are arithmetic illustrations. The study did not establish a rule that predicts how much a given person will regain. STEP 1 extension

The study’s averages also cannot resolve a question that matters at the point of stopping. The trials did not assign people to leave treatment because of nausea, an insurance decision or satisfaction with their progress. Each circumstance can bring a different duration of treatment, different follow-up and different options for what comes next. Random assignment in STEP 4 strengthens the estimate for the switch that researchers actually tested. Applying it to a person who stops earlier, uses a different formulation or switches to another drug requires an additional assumption. STEP 4 randomized trial · STEP 1 extension

The designs also leave a gap around gradual withdrawal. STEP 4 compared continuing the injection with switching to placebo. STEP 1 followed people after the treatment phase ended. Neither design put a taper and a direct stop head to head under the same conditions. To estimate whether tapering changes regain, a trial would need to give otherwise comparable groups different stopping schedules, track them for the same length of time after their final injection and account for other treatments begun during follow-up. The published weight curves give a reason to ask that question and leave its answer open. STEP 4 randomized trial · STEP 1 extension

What a laboratory lunch can tell us about appetite

Semaglutide acts on the GLP-1 receptor, and experiments suggest that reduced food intake may help explain some of the weight loss during treatment. In a 72-person randomized study, researchers offered participants a lunch they could eat freely after 20 weeks on semaglutide or placebo. The semaglutide group consumed about 35% less energy at that lunch. Participants also reported less hunger and fewer cravings. The investigators used absorption of paracetamol as an indirect measure of gastric emptying and found no evidence of delayed emptying at week 20 by that measure. The result supports a role for appetite and intake under the conditions tested. Twenty-week appetite and meal study

A 60-week randomized study published in 2026 suggests why the timing of that lunch matters. Differences in several self-reported appetite measures were detectable at week 20, while the same between-group differences were statistically unclear at weeks 40 and 60. Those ratings capture what participants reported at study visits. Energy intake at a test meal captures what they ate in a controlled setting. Each measure has a different relationship to what a person routinely eats at home over months. Sixty-week appetite trial

Stopping semaglutide may remove some of the appetite effects that helped sustain weight loss. That explanation fits the meal experiments and the direction of the withdrawal results, but the trials cannot trace a specific amount of regain to a specific change in hunger. Doing that would require repeated measures of appetite and intake before and after the final injection, along with a way to distinguish the effect of withdrawal from changes associated with the weight already lost. For now, the scale provides stronger evidence for the direction of the average change than the laboratory meal provides for its precise cause. Twenty-week appetite and meal study · Sixty-week appetite trial · STEP 4 randomized trial

What the scale leaves out as people get older

In the STEP 1 extension, many measures of cardiometabolic health moved back toward their starting values during the year off treatment. Average blood pressure, for example, moved back toward baseline in the group formerly assigned semaglutide. This suggests that some changes measured during treatment may fade as weight returns and the drug is withdrawn. As both occurred during the same period, the extension cannot isolate how much of the change followed from regained weight or from losing a direct drug effect. It also did not test whether the shifts after withdrawal translated into more heart attacks or strokes. STEP 1 extension

A separate, exploratory STEP 1 analysis shows why the composition of the weight change matters. In a subgroup of 140 people assessed with DXA scans, semaglutide recipients lost fat mass and lean mass during treatment, while the share of their body weight classified as lean increased. Both findings can coexist when fat mass falls more sharply. The scan’s estimate of lean mass includes tissue and water beyond skeletal muscle, and the analysis did not measure how the regained weight after stopping divided between fat and lean tissue. STEP 1 body composition analysis

For an older person who values being able to rise from a low chair or carry groceries, that distinction is consequential. Two people could finish the year at the same weight and differ in strength or in how easily they get around. An adequate study of healthy aging after withdrawal would need to measure those functions directly, alongside weight and body composition. It would also need enough older participants with limited strength or mobility at the outset to estimate their outcomes separately. The mean age at randomization in STEP 4 was about 46, which limits what that trial alone can say about people in their seventies or eighties. STEP 4 randomized trial · STEP 1 body composition analysis

The continuation arm gives a clear comparison for the following 48 weeks among people who had already tolerated treatment. It cannot establish the balance of benefits and burdens over decades. Even within that selected group, gastrointestinal complaints were reported more often with continued semaglutide than with placebo during the randomized phase. When a treatment decision extends beyond one year, the trial supports expecting some average regain after stopping and leaves questions about long-term tolerability, day-to-day function and the weight trajectory beyond follow-up. STEP 4 randomized trial · STEP 1 extension

Frequently asked questions

How much weight might return after stopping Wegovy? In one study extension, people regained about two-thirds of the average weight they had lost over the next year. Individual outcomes varied.

Does tapering Wegovy help keep the weight off? The STEP withdrawal studies did not compare gradual tapering with a direct stop, so they cannot show whether tapering changes regain.

Does regained weight tell you whether muscle returned? Scale weight alone cannot show how much of the regain was muscle, fat or water, or how strength changed.


This article summarises published research and is not medical advice. Consult your healthcare provider before changing your routine.

Frequently Asked Questions

How much weight might return after stopping Wegovy?
In one study extension, people regained about two-thirds of the average weight they had lost over the next year. Individual outcomes varied.
Does tapering Wegovy help keep the weight off?
The STEP withdrawal studies did not compare gradual tapering with a direct stop, so they cannot show whether tapering changes regain.
Does regained weight tell you whether muscle returned?
Scale weight alone cannot show how much of the regain was muscle, fat or water, or how strength changed.

Sources

  1. Rubino et al., STEP 4 randomized withdrawal trial, JAMA(2026)
  2. Wilding et al., STEP 1 trial extension, Diabetes, Obesity and Metabolism(2026)
  3. Friedrichsen et al., 20-week semaglutide appetite and meal study, Diabetes, Obesity and Metabolism(2026)
  4. Sixty-week randomized semaglutide trial on energy intake, appetite and food reward, American Journal of Clinical Nutrition(2026)
  5. Wilding et al., exploratory STEP 1 body composition analysis, Journal of the Endocrine Society(2026)
Wegovy semaglutide weight regain GLP-1 clinical trials

Stay Updated on Longevity Science

Weekly research digests. No spam, unsubscribe anytime.

Subscribe

Related Articles